The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Casgevy is the first drug to be licensed based on CRISPR, a gene-editing technique for which its discoverers won a Nobel Prize in 2020. It has also been submitted for approval in the US and EU ...

The Food and Drug Administration approval in December 2023 of the first CRISPR therapeutic, Casgevy to treat sickle cell, came 11 years after the discovery of the revolutionary gene-editing technology ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

In a shift away from GMOS, aka genetically modified organisms, important research is continuing in gene editing, sometimes ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors. If you select quality ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...